BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 37167811)

  • 1. DNA aneuploidy identifies a subset of Luminal subtype breast carcinoma patients with worse clinical outcome.
    Pinto AE; Matos J; Pereira T; Silva GL; André S
    Pathol Res Pract; 2023 Jun; 246():154513. PubMed ID: 37167811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women.
    Cortesi L; De Matteis E; Cirilli C; Marcheselli L; Proietto M; Federico M
    Tumori; 2012 Nov; 98(6):743-50. PubMed ID: 23389361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy.
    Chen XS; Wu JY; Huang O; Chen CM; Wu J; Lu JS; Shao ZM; Shen ZZ; Shen KW
    Oncol Rep; 2010 May; 23(5):1213-20. PubMed ID: 20372832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
    Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
    Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
    Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
    Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological Characteristics and Long-term Outcomes in Node-negative Breast Cancer.
    Agostinetto E; Giordano L; Torrisi R; De Sanctis R; Masci G; Losurdo A; Zuradelli M; Tinterri C; Gatzemeier W; Testori A; Alloisio M; De Rose F; Fernandes B; Santoro A
    Clin Breast Cancer; 2020 Aug; 20(4):e481-e489. PubMed ID: 32279915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.
    Kneubil MC; Brollo J; Botteri E; Curigliano G; Rotmensz N; Goldhirsch A; Lohsiriwat V; Manconi A; Martella S; Santillo B; Petit JY; Rietjens M
    Eur J Surg Oncol; 2013 Mar; 39(3):260-5. PubMed ID: 23313014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
    Wu SY; Tan Y; Guan YS
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aneuploidy identifies subsets of patients with poor clinical outcome in grade 1 and grade 2 breast cancer.
    Pinto AE; Pereira T; Silva GL; André S
    Breast; 2015 Aug; 24(4):449-55. PubMed ID: 25920680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
    Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
    Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy.
    Chen S; Huang L; Chen CM; Shao ZM
    Oncotarget; 2015 Jul; 6(20):18174-82. PubMed ID: 26053183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular phenotypes of DCIS predict overall and invasive recurrence.
    Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
    Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
    Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
    JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score.
    Yang ZJ; Liu YX; Huang Y; Chen ZJ; Zhang HZ; Yu Y; Wang X; Cao XC
    Cancer Med; 2023 Feb; 12(3):2493-2504. PubMed ID: 35909232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
    Liu ZF; Chen C; Yao XL; Sun SR
    Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.
    Chen XS; Ma CD; Wu JY; Yang WT; Lu HF; Wu J; Lu JS; Shao ZM; Shen ZZ; Shen KW
    Tumori; 2010; 96(1):103-10. PubMed ID: 20437866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features and survival analysis of T1mic, a, bN0M0 breast cancer.
    Li J; Liu X; Tong Z
    Jpn J Clin Oncol; 2012 Jun; 42(6):471-6. PubMed ID: 22493058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information.
    Feeley LP; Mulligan AM; Pinnaduwage D; Bull SB; Andrulis IL
    Mod Pathol; 2014 Apr; 27(4):554-61. PubMed ID: 24051696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.